Advancing the Care of Pancreatic Cancer Patients: Moving Beyond Just Tumour Tissue.

IF 3.4 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Biomarker Insights Pub Date : 2021-10-11 eCollection Date: 2021-01-01 DOI:10.1177/11772719211049852
Steve E Kalloger, Joanna M Karasinska, Cassia Warren, Daniel J Renouf, David F Schaeffer
{"title":"Advancing the Care of Pancreatic Cancer Patients: Moving Beyond Just Tumour Tissue.","authors":"Steve E Kalloger,&nbsp;Joanna M Karasinska,&nbsp;Cassia Warren,&nbsp;Daniel J Renouf,&nbsp;David F Schaeffer","doi":"10.1177/11772719211049852","DOIUrl":null,"url":null,"abstract":"<p><p>Biobanking efforts, to establish and grow the pool of available tissue from which evidence on aetiology, therapeutic susceptibility and prognosis of various diseases, have been underway for decades. This is illustrated nowhere better than in cancer. High incidence cancers such as breast, colorectal and lung have seen massive increases in their requisite formularies that have yielded improved prognoses. These discoveries, on a very fundamental level, were made by scientists who had access to tumour tissue and associated clinical data from patient donors. As the research space for higher incidence malignancies became increasingly crowded, attention has turned towards those malignancies with lower incidence. In the same time span, technology has continued to evolve, allowing the next generation of scientists and clinicians to ask more nuanced questions. Inquiries are no longer limited to the -omics of tumour tissue but also include biomarkers of blood and excretory products, concurrent disease status and composition of the gut microbiome. The impact of these new technologies and the questions now facing researchers in low-incidence cancers will be summarized and discussed. Our experience with pancreatic ductal adenocarcinoma will be used as a model for this review.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2021-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/37/55/10.1177_11772719211049852.PMC8512230.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarker Insights","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11772719211049852","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Biobanking efforts, to establish and grow the pool of available tissue from which evidence on aetiology, therapeutic susceptibility and prognosis of various diseases, have been underway for decades. This is illustrated nowhere better than in cancer. High incidence cancers such as breast, colorectal and lung have seen massive increases in their requisite formularies that have yielded improved prognoses. These discoveries, on a very fundamental level, were made by scientists who had access to tumour tissue and associated clinical data from patient donors. As the research space for higher incidence malignancies became increasingly crowded, attention has turned towards those malignancies with lower incidence. In the same time span, technology has continued to evolve, allowing the next generation of scientists and clinicians to ask more nuanced questions. Inquiries are no longer limited to the -omics of tumour tissue but also include biomarkers of blood and excretory products, concurrent disease status and composition of the gut microbiome. The impact of these new technologies and the questions now facing researchers in low-incidence cancers will be summarized and discussed. Our experience with pancreatic ductal adenocarcinoma will be used as a model for this review.

Abstract Image

Abstract Image

Abstract Image

推进胰腺癌患者的护理:超越肿瘤组织。
生物银行的工作已经进行了几十年,目的是建立和发展可用组织库,从中提供各种疾病的病因学、治疗易感性和预后的证据。没有什么比癌症更能说明这一点了。乳腺癌、结肠直肠癌和肺癌等高发癌症的必要处方大幅增加,预后得到改善。这些发现,在一个非常基本的层面上,是由能够接触到肿瘤组织和来自患者捐赠者的相关临床数据的科学家做出的。随着高发病率恶性肿瘤的研究空间日益拥挤,人们的注意力转向了低发病率恶性肿瘤。与此同时,技术不断发展,使下一代科学家和临床医生能够提出更细微的问题。调查不再局限于肿瘤组织的组学,还包括血液和排泄产物的生物标志物,并发疾病状态和肠道微生物组的组成。总结和讨论这些新技术的影响以及低发病率癌症研究人员目前面临的问题。我们在胰腺导管腺癌方面的经验将被用作本综述的模型。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Biomarker Insights
Biomarker Insights MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
6.00
自引率
0.00%
发文量
26
审稿时长
8 weeks
期刊介绍: An open access, peer reviewed electronic journal that covers all aspects of biomarker research and clinical applications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信